Endocyte Cash Flow - Quarterly (NASDAQ:ECYT)

Add to My Stocks
$17.54 $0.43 (2.39%) ECYT stock closing price Sep 19, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Endocyte needs to disclose. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Endocyte profits one has to check the income statement and for Endocyte debt one has to check the balance sheet. This statement can tell if a company is running out of money while still being profitable and is useful in Endocyte stock analysis. Endocyte had a negative net income cash flow of $-20.17M till this quarter of 2018 Q2. This report is very useful in measuring the short term viability of a company. Endocyte saw a outflow of $-62.13M from investing activities till 2018 Q2.

View and download details of Endocyte cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-20.17M-8.6M-55.06M-46.5M-23.23M-11.48M-43.88M-32.82M-24.11M-10.15M
Depreciation Depletion Amortization Cash-Flow-0.19M-----1.31M1.01M--
Net Increase (Decrease) in Assets Liabilities-1.18M-0.46M-0.17M-0.9M--0.41M-1.4M-2.18M-1.66M-2.48M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.78M1.35M20.81M19.28M2.1M1.13M9.32M7.88M6.54M2.08M
Net Cash from (used by) Operating Activities
-18.76M-7.7M-33.65M-27.41M-19.79M-10.48M-34.65M-26.1M-18.52M-10.13M
Increase (Decrease) in Prop Plant And Equipment---0.06M-0.04M-0.04M-0.02M-0.71M-0.66M-0.46M-0.03M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-62.21M-4.2M28.2M51.11M53.47M13.02M50.83M45.96M30.05M34.91M
Other Cash Inflow (Outflow) from Investment Activities---12.77M-12.32M------
Net Cash from (used by) Investment Activities
-62.13M-4.16M15.36M38.74M53.42M12.99M50.11M45.29M29.58M34.87M
Issuance (Purchase) of Equity Shares87.38M83.13M5.62M4.61M--0.07M----0.01M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
87.38M83.13M5.62M4.61M--0.07M----0.01M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
6.49M71.27M-12.66M15.95M33.7M2.43M15.79M19.3M11.15M24.72M
Cash & Equivalents at Beginning of Year18.56M31.22M15.43M45.53M52.84M33.99M61.35M16.87M8.69M-
Cash & Equivalents at Year End25.04M89.83M18.55M47.17M64.92M33.66M31.22M34.73M26.58M40.15M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Endocyte stock price history provides the price history of a stock, Endocyte stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Endocyte saw a negative change in Net Change in Cash and Cash Equivalents of $6.49M till 2018 Q2. Apart from the Endocyte stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Endocyte decreased its cash from operating activities to $-18.76M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a negative value of $-62.13M for ECYT stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $87.38M for Endocyte. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Endocyte Cash Flow